Skip to main content
AMARIN CORP PLC\UK logo

AMARIN CORP PLC\UK — Investor Relations & Filings

Ticker · AMRN ISIN · US0231114044 US Manufacturing
Open in API
Filings indexed 1,173 across all filing types
Latest filing 2026-05-14 Declaration of Voting R…
Country US United States of America
Listing US AMRN

About AMARIN CORP PLC\UK

https://amarincorp.com/

Amarin Corporation plc is a pharmaceutical company focused on the development and commercialization of therapeutics to improve cardiovascular health. The company's primary mission is to address the persistent cardiovascular risk that remains for many patients despite standard therapies. Its lead product, Vascepa (icosapent ethyl), is a prescription-grade omega-3 fatty acid used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia and to reduce the risk of cardiovascular events in certain high-risk patient groups. Amarin is dedicated to creating a new paradigm in cardiovascular disease management to help prevent heart attacks and strokes for patients worldwide.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 87% confidence The document is a SEC Form 8-K “Current Report” under Item 5.07, detailing the submission of matters to a vote of security holders at the Annual General Meeting. It provides the official voting results on director elections, say-on-pay, share issuance authorization, incentive plan proposals, and related resolutions. This type of filing—providing detailed vote tallies for shareholder matters—is categorized as a Declaration of Voting Results & Voting Rights Announcement.
2026-05-14 English
10-Q - AMARIN CORP PLC\UK (0000897448) (Filer)
Interim / Quarterly Report Q1 2026
2026-04-29 English
8-K - AMARIN CORP PLC\UK (0000897448) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 29, 2026, reporting the issuance of a press release announcing financial results for the quarter ended March 31, 2026. The text explicitly states that the press release is furnished as an exhibit and that the information is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release containing the results. The length of the document is 3806 characters, which is relatively short and consistent with a current report announcing earnings results rather than the earnings release itself. According to the classification rules, initial announcements of quarterly financial results (key highlights only) are classified as Earnings Release (ER). However, since this document is a Form 8-K furnishing a press release announcing earnings results, it is effectively an Earnings Release filing. Therefore, the appropriate classification is ER with high confidence.
2026-04-29 English
ARS - AMARIN CORP PLC\UK (0000897448) (Filer)
Annual Report
2026-04-10 English
DEF 14A - AMARIN CORP PLC\UK (0000897448) (Filer)
Proxy Solicitation & Information Statement
2026-04-10 English
PRE 14A
Regulatory Filings
2026-03-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.